01
Cash & equivalents increased 137.8%
Cash & equivalents changed +137.8% from the comparable as-filed period.
$114.6M→$272.6MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTIDEAYA Biosciences, Inc.'s latest supported as-filed period reports revenue of $8.9M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +137.8% from the comparable as-filed period.
Net income changed -45.1% from the comparable as-filed period.
Operating income changed -37.7% from the comparable as-filed period.
Research & development changed +46.4% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
IDYA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-332774SEC ↗8-KAug 4, 2026Period Aug 4, 20260001193125-26-331381SEC ↗4Jul 9, 2026Period Jul 7, 20260001610717-26-000336SEC ↗8-KJun 23, 2026Period Jun 16, 20260001193125-26-279427SEC ↗4Jun 18, 2026Period Jun 16, 20260001610717-26-000265SEC ↗4Jun 18, 2026Period Jun 16, 20260001610717-26-000264SEC ↗4Jun 18, 2026Period Jun 16, 20260001610717-26-000263SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 7, 2026Filed Jul 9, 2026 | Ruiz Briseno AndresChief Accounting Officer | Option ExerciseDirect | 9,550 | $13 | $122,813 | Form 4 ↗ |
| Jul 7, 2026Filed Jul 9, 2026 | Ruiz Briseno AndresChief Accounting Officer | Open Market SaleDirect | 9,550 | $40 | $382,131 | Form 4 ↗ |
| Jul 7, 2026Filed Jul 9, 2026 | Ruiz Briseno AndresChief Accounting Officer | Option ExerciseDirect | 9,550 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Stock-based compensation changed +40.4% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001610717-26-000261